Qinggan Mingshi Granules Inhibited Ferroptosis to Treat Diabetic Retinopathy in Mice Through NRF2/GPX4 Axis
Journal of Diabetes Research · 2026
DOI: 10.1155/jdr/9978155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, 2026. Verfasst von Zhongyong Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Cangzhou, Hebei, China. Hauptthemen laut MEDLINE: Ferroptosis, NF-E2-Related Factor 2, Phospholipid Hydroperoxide Glutathione Peroxidase, Diabetic Retinopathy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Diabetic retinopathy (DR) is a common microvascular complication of diabetes, which seriously affected the life quality in diabetic patients. Developing novel therapy to improve DR is essential. Qinggan Mingshi granules (QGMS) have been demonstrated with protective effects on DR clinically. However, the mechanisms of QGMS remain unclear.
Method
In order to more thoroughly investigate the mechanism underlying the positive effects of QGMS on DR, a mouse model of DR was established in this study, and the positive effects of QGMS on the DR mice were observed. Next, the effects of QGMS on ferroptosis and the NRF2/GPX4 axis were investigated. In addition, we used an NRF2 inhibitor to determine whether QGMS inhibits ferroptosis in DR mice via the NRF2/GPX4 axis.
Result
Our results revealed the therapeutic effects of QGMS on DR including improving the permeability of blood–retina barrier (BRB), reducing the pathological changes and ferroptosis in retina. QGMS also induced the expression of NRF2/GPX4 axis in retina. Furthermore, ML385, an NRF2 inhibitor, abolished the effects of QGMS on DR.
Conclusion
This study revealed that QGMS can effectively treat DR by alleviating retinal damage through enhancing the expression of NRF2/GPX4 axis‐related proteins and thus scavenging of LPOs, ultimately reducing ferroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Cangzhou, Hebei, China.
- Department of Ophthalmology, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine of Hebei, Cangzhou, Hebei, China.
ORCID-Profile: Zhongyong Zhang, Shuquan Lv, Yuansong Wang
Zitieren
APA
Zhang, Z., Jin, Q., Zhao, H., Liu, Y., Wang, M., Han, Z., Wu, J., Lv, S., Wang, X., Chen, W., Wang, Q., Bai, H., & Wang, Y. (2026). Qinggan Mingshi Granules Inhibited Ferroptosis to Treat Diabetic Retinopathy in Mice Through NRF2/GPX4 Axis. Journal of Diabetes Research. https://doi.org/10.1155/jdr/9978155
Vancouver
Zhang Z, Jin Q, Zhao H, Liu Y, Wang M, Han Z, et al. Qinggan Mingshi Granules Inhibited Ferroptosis to Treat Diabetic Retinopathy in Mice Through NRF2/GPX4 Axis. Journal of Diabetes Research. 2026. doi:10.1155/jdr/9978155
BibTeX
@article{Zhang2026,
author = {Zhang, Zhongyong and Jin, Qianqian and Zhao, Hongmin and Liu, Yingkai and Wang, Meng and Han, Zhongqian and Wu, Jin and Lv, Shuquan and Wang, Xiaoyun and Chen, Wei and Wang, Qingjin and Bai, Hailong and Wang, Yuansong},
title = {Qinggan Mingshi Granules Inhibited Ferroptosis to Treat Diabetic Retinopathy in Mice Through NRF2/GPX4 Axis},
journal = {Journal of Diabetes Research},
year = {2026},
doi = {10.1155/jdr/9978155}
}
EUVIMED